-Anadys Pharmaceuticals Inc Initiates Dosing in Phase Iib Trial of Ana598 in Hepatitis C Patients
M2 EquityBites › January 27, 2011
Linked as:
Summary
EQUITYBITES-(C)2011 M2 COMMUNICATIONS
Biopharmaceutical company Anadys Pharmaceuticals Inc (Nasdaq:ANDS) said on Wednesday that it has begun dosing in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.See the full content of this document
Extract
-Anadys Pharmaceuticals Inc Initiates Dosing in Phase Iib Trial of Ana598 in Hepatitis C Patients
The company said its direct-ac...
See the full content of this document
Sponsored links
